To the Editor: In her Editorial on the risks and benefits of human papillomavirus (HPV) vaccination, Dr Haug stated that data on vaccine efficacy, as measured by prevention of precancerous lesions (cervical intraepithelial neoplasias grades 2 and 3 [CIN 2/3]), were not reported until May 2007.1 That would have been almost a year after the US Food and Drug Administration (FDA) licensed the vaccine and the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination of girls aged 11 to 12 years. She also noted that professional medical associations provided members with educational materials more than a year before the data on the important end point of CIN 2/3 were published.
Baylor NW, Wharton M. Efficacy Data and HPV Vaccination Studies. JAMA. 2009;302(24):2658-2660. doi:10.1001/jama.2009.1882